创胜集团-B：截至2024年12月31日止年度的全年业绩公告;及变更所得款项用途

20241231 2024123120231231 •2023123153.842.52024123111.3CDMO •2023123137.313.82024123123.520241231 •202312312.422.62024123120.2 •20231231382.0189.920241231192.1 •20231231117.446.92024123170.5 •20231231465.7171.420241231294.3 •2023123153.842.52024123111.3CDMO •2023123137.313.82024123123.520241231 •20231231372.5194.420241231178.1 •2023123198.638.12024123160.5 •20231231437.3166.920241231270.4 Claudin18.2osemitamab (TST001)(G/GEJ)(FDA)()(MFDS)9ESMO()2024osemitamab (TST001)(G/GEJ)(TranStar102) GCLDN18.2PD-L1(PFS)14.268%III(TranStar301)osemitamab (TST001)Claudin18.2(G/GEJ)(G/GEJ)Claudin18.220248Claudin18.2202411Claudin18.220253Claudin18.2 blosozumab (TST002)42024WCO-IOFESCEO(SAD)1,200mgblosozumab (TST002)85BMD3.52%6.20%BMD1.30%2.24%BMD(2.77%) 202412(SABCS)TST013TST013LIV-1(ADC)I(TNBC)MMAEADC 2024TST801INDTST801BAFFTACIBAFFAPRILTACIB(SLE)(LN)IgA(IgAN)TST801 HiCBosemitamab (TST001)GMP OsemitamabTST001ADCCClaudin18.2 •2 0 2 442 0 2 4( A A C R )TranStar101PKOsemitamab (TST001)TranStar102 •20246(ASCO)osemitamab(TST001)CAPOXTranStar102GCLDN18.2PD-L1 CPSClaudin18.2PDL1(PFS)12.6IIICLDN18.2 •20248Claudin18.2202411Claudin18.2 •20249ESMOosemitamab (TST001)CAPOX(TranStar102)GCLDN18.2PD-L1PFSPFS14.268%82CLDN18.21273.8% Osemitamab (TST001)(CDx) •CDxClaudin18.2(CDx)osemitamab (TST001)Claudin18.2TranStar301III20244AACRosemitamab (TST001)III Blosozumab (TST002) •Blosozumab (TST002) SAD2024WCO-IOF-ESCEO42024(CSOBMR)1,200 mgblosozumab (TST002)85BMD3.52%6.20%BMD1.30%2.24%BMD(2.77%) TST003GREMLIN-1 •TST003-1001FIHTST003PK •2024AACRTST003-1001(TiP) TST105ADC •TST105FGFR2b(ADC)FGFR2bADC TST013ADC •TST013LIV-1ADCLIV-1ADCTOPO-IPKADCINDADCTST013 •2024122024(SABCS)TST013LIV-1ADCITNBCMMAEADCLIV-1 ADCADC-1ADC-2I(Topo I)TNBCADCMMAEADCADC-1ADC-2LIV-1Topo ILIV-1ADCADC-1ADC-2LIV-1 TST801 •TST801BAFFTACIBAFFAPRILTACIBSLELNIgANTST801BINDBAFFBDNA (dsDNA)A (IgA)M (IgM)G(IgG) TST808B •TST808BTST808BTST808IgANIND •BMSTranStar102osemitamab(TST001)2TranStar101 •C l a u d i n18.2C D xosemitamab(TST001)TranStar301III •osemitamab (TST001) • • •(HiCB) •siRNAsiRNACDMO •ExcelPro CHOCHOExcelPro CHO CMCCDMO CMC •osemitamab (TST001)FDA Cosemitamab (TST001) •CDMO • •CDMO CDMO •siRNA•ADC• osemitamab (TST001)FDA(MFDS)osemitamab (TST001)Claudin18.2IIIClaudin18.2 CMCHiCBCMCCDMO 15blosozumab (TST002) PD-L1=1TGFβ=βMASP2=2IND=FIC=HPV=NSCLC=SLE=LN=TMA=IgA=AMono=Combo=Chemo=VEGFR2=2 (1)2021914 (2) TST001TST002 TST004 TST801TST808TST003TST008 osemitamab (TST001)MSB0254 TST003 TST105 TST012TST013 •Osemitamab(TST001)Claudin18.2III(TranStar301)osemitamab (TST001)Claudin18.2FDA(MFDS)Claudin18.2 •MSB0254VEGFR2 •TST003GREMLIN-1 •TST012FGFR2bADC •TST105FGFR2bADC •TST013LIV-1ADC MSB0254TST003osemitamab(TST001)osemitamab(TST001)Claudin18.2TST003MSB0254 Osemitamab (TST001)ADCCClaudin18.2 Osemitamab (TST001)Claudin18.2ADCCClaudin18.2(PDAC)osemitamab (TST001)+Claudin18.2PDAC Claudin18.2Claudin18.2III38%Osemitamab(TST001)Claudin18.2ADCCADCCClaudin18.2osemitamab (TST001)~55%osemitamab (TST001)Claudin18.2 2024osemitamab (TST001) •202442024AACRTranStar101PKOsemitamab(TST001)TranStar102 •20246ASCOosemitamab (TST001)CAPOXTranStar102GCLDN18.2PD-L1 CPS(H/M) Claudin18.2PDL1(PFS)PFS12.6IIICLDN18.2 •20248Claudin18.2202411Claudin18.2 •20249ESMOosemitamab(TST001)CAPOX(TranStar102)GCLDN18.2PDL1PFSPFS14.268%82CLDN18.21273.8% Osemitamab (TST001)CDx •CDxClaudin18.2(CDx)osemitamab (TST001)Claudin18.2TranStar301III20244AACRosemitamab (TST001)III MSB0254VEGFR2 MSB0254VEGFR2MSB0254VEGFR-2VEGFR-2VEGFR-2IRP2DVEGFR2MSB0254 TST003GREMLIN-1 TST003GREMLIN-1FIH •TST003-1001FIHTST003PK•2024AACRTST003-1001(TiP) TST012FGFR2bADC TST012FGFR2bADCosemitamab(TST001) TST105ADC TST105FGFR2b(ADC)FGFR2bADC •2024ADC TST013ADC TST013LIV-1ADCLIV-1ADCTOPO-IPKADCADCTST013 •2024IND •2024122024(SABCS)TST013TNBCILIV-1ADCMMAEADCLIV-1 ADCADC-1ADC-2I(Topo I)TNBCADCMMAEADCADC-1ADC-2LIV-1Topo ILIV-1ADCADC-1ADC-2LIV-1 blosozumab (TST002)TST004TST008 TST801TST808 blosozumab (TST002)IITST801IgA(SLE)1844 Blosozumab (TST002) Blosozumab (TST002)blosozumabIIblosozumab(BMD)12blosozumabBMD17.7%BMD6.2%32blosozumab (TST002)851,200 mgblosozumab(TST002)85BMD3.52%6.20%BMD1.30%2.24%PK/PD •Blosozumab (TST002) SAD42024WCO-IOF-ESCEO2024(CSOBMR)1,200 mgblosozumab (TST002)85BMD3.52%6.20%BMD1.30%2.24%BMD(2.77%) TST004IgANMASP-2 T S T 0 0 42(MASP2)TST004IgANMASP2I TST008MASP-2BAFF TST008MASP2B TST801 TST801BAFFTACIBAFFAPRILTACIBSLELNIgANTST801BINDBAFFBdsDNAIgA IgMIgG •2024IND TST808B TST808BTST808BTST808IgAN •2024IND 18A.08(3) ADCCADCSLEINDB osemitamab (TST001)BMSblosozumab (TST002)TST004ADC Osemitamab (TST001) osemitamab (TST001)Claudin18.2PDAC 2 0 2 2( B M S )osemitamab (TST001)®PD-1Claudin18.2BMS o s e m i t a m a b( T S T001)Claudin18.2Claudin18.2osemitamab (TST001)Claudin18.2osemitamab (TST001)III(TranStar301) Claudin18.2CDxIII(TranStar301) osemitamab (TST001) Blosozumab (TST002) 2019LY-2541546 (blosozumab)LY-3108653LY-2950913 blosozuma